bluuebunny/crossref_metadata_2025_split huggingface dataset:
Are Risky Banks Disciplined by Large Corporate Depositors?
Authors: IMBIEROWICZ BJÖRN , SAUNDERS ANTHONY , STEFFEN SASCHA 
Published: November 2024

AbstractWe analyze depositor discipline using auctions of unsecured money market deposits of firms to banks. In each auction, only the firm observes the banks and their interest rate bids. We observe that deposit interest rate bids increase with bank risk. Conditional on the same interest rate bid and firm–bank relationship, depositors select less risky banks. Banks reduce their risk after their deposit offers are less often selected. Risky banks eventually exit the market, and reenter when they become safer. This has important implications for banks’ access to unsecured corporate funding, financial stability, and our understanding of market discipline more broadly.
Mapping microfinance research to sustainable development goals: Insights from Scientometrics and BERTopic analysis
Authors: Pattnaik Debidutta , Hassan M. Kabir 
Published: November 2024

AbstractMicrofinance research plays a pivotal role in addressing global development challenges, yet comprehensive assessments of its alignment with sustainable development goals (SDGs) remain scarce. This study fills this gap by systematically mapping the landscape of microfinance literature to its corresponding SDG contributions. Leveraging data from Scopus and SCIval, we analyzed 1004 microfinance articles spanning between 2014 and 2023. Our findings reveal a substantial body of research focused on poverty alleviation (SDG 1) and economic empowerment (SDG 8), with notable attention to gender equality (SDG 5) and reduced inequalities (SDG 10). Key thematic clusters include the performance and impact of microfinance institutions (MFIs), microinsurance innovations, and Islamic microfinance. Notably, top‐cited articles underscored the sector's commitment to poverty alleviation and economic growth, with a nuanced exploration of gender dynamics and rural household impacts. Furthermore, our BERTopic analysis unveils the multidimensional nature of microfinance research, highlighting prevalent themes such as MFI performance and rural household impact. Geographically, research efforts are concentrated in the United States, India, and France, reflecting a global commitment to SDG‐aligned microfinance interventions. The paper's theoretical contributions lie in its framework development, interdisciplinary engagement, nuanced understanding of microfinance themes, global perspective, and methodological advancements, all of which enhance the scholarly discourse on microfinance's role in achieving SDGs.
Accuracy of different maxillomandibular relationship recording techniques in the edentulous maxillary arch
Authors: Pletkus Justinas , Auškalnis Liudas , Gendvilienė Ieva , Pletkus Rolandas , Eyüboğlu Tan Fırat , Özcan Mutlu , Akulauskas Mykolas , Rutkūnas Vygandas 
Published: November 2024

AbstractPurposeThis study investigated the effect of three digital bite registration techniques on the accuracy of intraoral scanning in maxillary edentulous and mandibular dentate arches.Materials and MethodsMaxillary edentulous and mandible fully dentate models were created. Four dental implants were placed in the maxilla, fitted with scan bodies, and reference scans were obtained using a Nikon Altera 10.7.6 scanner. Digital impressions were acquired 10 times for each model using a Trios 4 intraoral scanner. Three different digital bite records were collected for each pair of mandible and maxilla scans. The first one was a bite record without additional material (WSB), the second utilized a silicone index between the models (WSB silicone), and the third followed a pre‐preparation scanning protocol (Pre‐PREP). The data was exported in standard tessellation language (STL) format, which was assessed for trueness and precision using statistical analysis.ResultsAccording to mean trueness values, WSB exhibited the lowest value, 173 µm, followed by WSB silicone 242 µm and Pre‐PREP 620 µm. The differences were significant only when comparing Pre‐PREP to WSB and Pre‐PREP to WSB silicone (p < 0.05). Regarding precision, WSB demonstrated a mean value of 171.5 µm, followed by WSB silicone with 213.8 µm, and Pre‐PREP with 222.2 µm with no significant difference between the groups.ConclusionThe presence of interarch bite registration material adversely affected interocclusal record accuracy, while WSB silicone presented a suitable substitute for WSB.
Kaposiform Hemangioendothelioma With Features of Congenital Hemangioma Treated With Sirolimus
Authors: Lee Danny , Sui Jennifer , Al‐Nabti Alreem , Schiff Deborah , Matiz Catalina , Naheedy John , Eichenfield Dawn Z. 
Published: November 2024

ABSTRACTKaposiform hemangioendothelioma (KHE) is a vascular neoplasm characterized by abnormal angiogenesis and lymphangiogenesis. Here, we present a case of a 19‐month‐old male with KHE of the right leg with bony involvement who was initially misdiagnosed with infantile hemangioma. Due to its heterogeneous presentation and frequent occurrence of comorbidities such as Kasabach‐Merritt phenomenon, clinical and pathological correlation is essential for diagnosis of KHE.
Clinical Implications of Catabolic and Anabolic Bone Changes in Psoriatic Arthritis
Authors: Schett Georg 
Published: November 2024

Psoriatic arthritis (PsA) is a complex inflammatory condition characterized by both catabolic and anabolic changes that significantly impact patient outcomes. Catabolic processes in PsA primarily manifest as bone erosions and joint destruction. These changes result from the inflammation triggered by cytokines, which promotes osteoclast activation and increased bone resorption. On the other hand, anabolic changes are observed through the formation of enthesiophytes, bony projections that develop at the sites where tendons and ligaments attach to bone. This process is often seen as compensatory response to chronic inflammation and mechanical stress. Clinicians should adopt a holistic approach that not only focuses on alleviating symptoms but also considers the long-term implications of these bone changes. Understanding the dynamics of catabolic and anabolic changes in PsA is essential for developing effective treatment strategies and improving patient outcomes. By recognizing the significance of both bone erosions and enthesiophyte formation, healthcare providers can better tailor their interventions, ensuring a comprehensive management plan that addresses both inflammation and structural integrity.
Efficient Management of Multiple Domains in Psoriatic Arthritis: Target Treatment Goals and Streamlined Clinical Assessment in a Short Session
Authors: Sewerin Philipp 
Published: November 2024

Psoriatic arthritis (PsA) is a chronic, immune-mediated, inflammatory arthropathy that presents with inflammation of the joints and entheses, including those of the axial skeleton, and is associated with increased mortality from cardiovascular diseases. Diagnosis is primarily based on clinical phenotype because of the diversity of the associated features, which can include skin and nail disease, dactylitis, uveitis, and arthritis. Early detection and timely management are crucial for improving clinical outcomes and patients’ quality of life. This lecture will focus on the management of the multiple domains in psoriatic arthritis and clinical insights on incorporating insights from clinical trials into daily clinical practice by streamlining clinical assessment in a short session. The lecture will begin by reviewing the epidemiology and pathophysiology of PsA, emphasizing the inflammatory nature of PsA. The clinical domains of PsA including skin psoriasis, arthritis, dactylitis, enthesitis and axial involvement will be discussed, highlighting the importance of targeting multiple PsA domains to improve PsA patient’s physical functions and quality of life. The lecture will then delve into the clinical management of PsA. We will discuss the current recommendations for PsA assessment, including measurement of different clinical domains of PsA. We will explore the PsA assessment in clinical trials and the streamlining strategies of assessment in real-life setting. The management strategies for PsA will then be focused, emphasizing the importance of targeting improvement in multiple clinical disease domains of PsA. We will explore the current evidence-based guidelines for pharmacological treatments, including the role of different biological disease-modifying antirheumatic drugs. Finally, the lecture will end with a real-world case sharing session, highlighting the importance of targeting multiple PsA domain by individualized treatment approaches to improve patient’s health outcomes and quality of life. This lecture aims to equip clinicians by overseas medical expertise on optimizing routine clinical management of multiple disease domains in PsA, ultimately facilitating individualized care to PsA patient to improve their overall clinical outcomes.
Unlocking JAKi Potential: Redefining Axial Spondyloarthritis Treatment Paradigms
Authors: Östör Andrew 
Published: November 2024

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily affects the axial skeleton, encompassing both radiographic and non-radiographic forms. The disease is characterized by chronic back pain and spinal stiffness, which are the most common symptoms. However, it often includes peripheral manifestations and extra-musculoskeletal symptoms as well, making the clinical presentation quite diverse. JAK inhibitors work by blocking the intracellular signaling pathways of several proinflammatory cytokines, which play a crucial role in the pathogenesis of inflammatory diseases. Given their proven efficacy in managing rheumatoid arthritis and their ability to mediate the signaling of cytokines involved in the pathogenesis of axSpA, JAK inhibitors have been the subject of numerous clinical trials in this context. The Assessment of SpondyloArthritis international Society and the European Alliance of Associations for Rheumatology (ASAS-EULAR) joint recommendations provide comprehensive guidance for the management of axSpA in 2022. The guideline introduced the use of Janus kinase inhibitors (JAKi), as a completely new drug class in the treatment landscape, with efficacy demonstrated in radiographic axSpA. JAKi was recommended, as a means to treatment intensification, in axSpA patients with persistently high disease activity despite conventional treatment. Since then, more trial data results have been released, showing efficacy in non-radiographic axSpA population as well. In this lecture, Professor Östör will delve into the critical role of shared decision-making in the management of axial spondyloarthritis. He will emphasize the importance of tailoring treatment plans to individual patient preferences and clinical profiles, a practice that is increasingly recognized as vital in achieving optimal outcomes. By examining current international guidelines and the latest study data, Professor Östör will provide a comprehensive overview of the benefit-risk profile of Upadacitinib in the treatment of axSpA. Professor Östör will also share his clinical experience with Upadacitinib, discussing various case studies to illustrate its application in real-world settings. This will include an exploration of how patient preferences and clinical profiles can influence treatment decisions, ensuring a personalized approach to managing this complex disease.
Pain in Inflammatory and Degenerative Joint Diseases
Authors: Hammer Hilde Berner 
Published: November 2024

The International Association for the Study of Pain (IASP) agreed in 2020 on a revised definition of pain: “An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage”. Patients with rheumatic diseases frequently report pain as a primary symptom. However, rheumatology healthcare providers often lack the training to adequately differentiate between different causes of pain, which are mandatory for optimal treatment. IASP classifies pain into 3 descriptive categories: nociceptive, neuropathic, and nociplastic pain. A recent review (Murphy AE et al, Arthritis Care & Research, 2023) gives a nice overview of these different forms of pain. Nociceptive pain derives from tissue injury, with subsequent sensation of pain by nociceptors. It is usually well-localized and can be precisely described by patients (i.e. rheumatoid arthritis, primary osteoarthritis) and there are localized pathologies that explain the pain symptoms. Neuropathic pain occurs with injury or insult to a peripheral or central nerve. There may be pressure on the nerve as in carpal tunnel syndrome, or changes in nerves caused by diabetes or other causes of nerve pathologies like mononeuritis multiplex. The pain and paresthesia typically follow the distribution of peripheral nerves in a dermatomal distribution. Nociplastic pain describes pain characterized by altered nociceptive processing (e.g., hypersensitivity), suggestive of dysregulation of CNS pain processing pathways. Nociplastic pain likely encompasses many different CNS pathways that lead to amplified processing of pain signals, decreased inhibition of pain, or both. Prototypical nociplastic pain conditions include both widespread (e.g., fibromyalgia) and localized conditions (e.g., chronic temporomandibular pain disorders and irritable bowel syndrome). Patients with inflammatory or degenerative joint diseases may have one, two or three of the presently described forms of pain, and an important objective for the rheumatologists is to understand which types of pain our patients are suffering from. About one-quarter of the patients with inflammatory rheumatic joint diseases have additional fibromyalgia causing increased scores of patient-reported outcomes like patient’s global VAS and number of tender joints, and this results in elevated composite scores independent on the degree of inflammation. Thus, rheumatologists must try to differentiate between nociceptive pain caused by inflammatory or degenerative pathologies which may be treated by different ant-inflammatory treatments, neuropathic pain which may need operative of medical treatment, or nociplastic pain which should be non-medically treated.
Thoracic Vertebral Fracture in a Female Case of Ankylosing Spondylitis Complicated with Turner Syndrome and Insufficient Response to Adalimumab
Authors: Wen Lin , Huang Jinxian 
Published: November 2024

Background: Ankylosing spondylitis (AS) is a chronic disease characterized by inflammatory back pain, with osteoporosis prevalence ranging from 18.7% to 62% 1. Vertebral fractures are four times more likely to occur 2. Turner syndrome (TS) is the most common sex chromosome abnormality in females, with a 1.4- to 2.2-fold increased likelihood of osteoporosis-related fractures 3. Seven cases of AS combined with TS with HLA-B27 positivity have been reported4. Methods: We report a case of a female patient with AS and TS who exhibited an inadequate response to adalimumab (ADA) and suffered a thoracic vertebral fracture. Results: A 41-year-old woman with HLA-B27 negative was diagnosed with AS in 2012 because of low back pain, and began ADA treatment in 2018. The patient had a past history of TS (45X/47XXX) with ultrasound revealing smaller than normal ovaries and uterus. Body weight was 54kg and height was 145cm (BMI25.68). She had primary amenorrhea, a wrist fracture at a young age, and a thoracic spine fracture in 2018. Bone mineral density (BMD) values for orthotopic lumbar vertebrae L1-L4 were 0.74 g/cm2, with Z-score of -2.7, and 0.564 g/cm2 at the left femoral neck with Z-score of -2.4. The FRAX tool predicted a 10-year fracture risk of 2.4% for the occurrence of major osteoporotic fracture (MOF), and a fracture risk of 0.9% for hip fracture. She initiated hormone replacement therapy (HRT). In November 2022, she discontinued ADA due to COVID-19 infection. Laboratory tests identified slightly elevated inflammatory markers (Fig. 1), low trough drug level of 0.31ug/ml and positive anti-drug antibody. In February 2023, she slipped in a snowdrift and experienced increased back pain. Spinal MRI revealed osteoporosis with a T7 compression fracture and a new T9 fracture (Figure 2 A,B). Sacroiliac (SI) joints MRI showed significant improvement of inflammation (Fig. 2 C,D). Spine surgery consultation suspected fracture attributed to obvious kyphosis deformity and stress concentration during falls, resulting in buckling compression. Repeated test determined a BMD value of 0.920 g/cm2 for orthotopic L3-L4 with a Z-score of -1.4, and a BMD value of 0.775 g/cm2 for the left total hip with a Z-score of -1.2, the 10-year probability of MOF was 3.2%, and that of hip fracture was 0.5%. She was diagnosed with severe osteoporosis due to recurrent fracture despite of BMD improvement and anti-osteoporosis medications were postponed. Conclusion: This case further proved the dominant role of disease co-morbidity and insufficient treatment in the unfavorable outcome regardless of genetic predisposition.
Contrasting Risk Profile in Idiopathic Inflammatory Myopathy (IIM) Patients with Cancer Before and After IIM Diagnosis
Authors: Tang Yan Ki Iris , Luk Lucas , Chan Dennis , Lai Billy , Ho Roy , Tang Vivian , Lee Patrick , So Ho 
Published: November 2024

Background: Patients with adult-onset idiopathic inflammatory myopathy (IIM) were at risk of cancer. While the recently published international guideline on cancer screening suggested cancer risk stratification in patients with newly diagnosed IIM, the difference in clinical and serological risk profile among patients with cancer diagnosed before and after IIM diagnosis remained uncertain. Methods: MyoHK was a longitudinal observational cohort that collected data from patients with rheumatologist diagnosis of IIM from 8 rheumatology centres in Hong Kong. Data were reviewed from 2004-2023 for this study. Patients with unavailable myositis specific antibody (MSA) were excluded from analysis. Occurrence of cancer 3 years before to 3 years after the diagnosis of IIM were documented. Patients with active cancer 3 years before diagnosis of IIM were classified to “Prior cancer” group and patients with cancer diagnosed at or within 3 years after IIM diagnosis were classified to “subsequent cancer” group. Patients were stratified to high, intermediate and standard cancer risks. Risk profile between the “prior cancer” and “subsequent cancer” groups were compared. Results: 501 patients were included in analysis. 82 patients had cancer within 3 years, in which 21 patients (25.6%) had cancer within 3 years preceding IIM diagnosis and 61 patients (74.4%) developed cancer at or within 3 years after IIM diagnosis. Nasopharyngeal, lung and breast cancers accounted for the top 3 cancers in both groups. In the “Prior cancer” group, patients were more likely to be female (85.7% vs 55.7%, p = 0.014) and were MSA-negative (33.3% vs 9.8%, p = 0.011). No patient in the “Prior cancer” group developed interstitial lung disease (0% vs 18.0%, p = 0.037) or fulfilled criteria for anti-synthetase syndrome (0% vs 13.1%, p = 0.062). Anti-TIF1g antibody was the most identified MSA in the two groups (42.9% vs 54.1%, p = 374). Myositis-associated-antibody (14.3% vs 42.6%, p = 0.019) and anti-Ro52 antibody (14.3% vs 37.7%, p = 0.047) were more common in the “subsequent cancer” group. In the overall cohort, 228 (45.5%), 246 (49.1%) and 27 (5.4%) of IIM patients were stratified into high, intermediate and standard cancer risk. Two-thirds of the “Prior cancer” group were stratified into high-risk while the remaining one-third being intermediate-risk, compared to 73.8% (p = 0.532) and 26.2% (p = 0.532) in the “subsequent cancer” group. Mortality between the two groups were comparable (38.1% vs 42.6%, p = 0.716). Conclusion: Compared to IIM patients with cancer detected at or after IIM diagnosis, patients with prior cancer were more likely to be female, negative for MSA and absence for ILD.
Biologics Therapy in Paediatric Rheumatic Diseases in Hong Kong
Authors: Chan Winnie KY , Ho Assunta CH , Chiang GPK , Yeung RHM , Kuok MCI , Chan AOM , Lam MHC , Kwong EYL 
Published: November 2024

Background: There is a substantial expansion in the number of biologics available for the treatment of JIA and childhood rheumatic disease over the past decades. However, there is no report on their use and safety profile in the local paediatric population. Method of study: This is a multi-centred retrospective cohort study, recruiting patients followed up in three Paediatric departments in Hong Kong. Subjects who were followed up for childhood-onset rheumatic diseases and was treated with any of the biologic DMARs on or before the 31st December 2022, were reviewed. Results: A total of 96 patients who received biologic DMARs in the studied period were reviewed. Sixty patients were diagnosed to have JIA, cSLE (10), uveitis (8), refractory KD (7), JDM (2), COVID-MISC (3), and others (6). Concerning the JIA group, male: female is 1.4:1. 38% of the patients had polyarticular JIA and 50% had ERA who failed conventional treatment with various cDMARS. Concerning the nature of biologics, 85% of JIA patients used different types of TNF-blockers, including etanercept (38.3%), adalimumab (40%), golimumab (5%) and infliximab (3.3%). Six JIA patients used tocilizumab and one used abatacept as second-line treatment after fail response to TNF-blockers. One JIA patient was on tofacitinib to avoid subcutaneous injection. For other biologics, infliximab for refractory KD (8), rituximab for cSLE and JDM (7 and 1), belimumab in cSLE (2) and anakinra in COVID-MISC (4). One JIA-ERA patient developed lymphoma six months after stopping adalimumab and recovered after chemotherapy. One cSLE patient received rituximab and developed EBV-related CNS lymphoma with repeated infections that required hospitalization. Most patients tolerated the biologic DMARs well without complications. There was no tuberculosis infection or activation. Two cSLE patients developed herpes zoster after rituximab infusion and required hospital treatment. Two patients on adalimumab developed recurrent folliculitis and one had to stop treatment. One patient developed bacteria endophthalmitis while on adalimumab. Four patients on adalimumab developed injection site reactions and one patient need to change to another biologic. One patient on adalimumab developed positive lupus serology without clinical features. Conclusion: A broad spectrum of biologics has been used in children with various rheumatic diseases without major complications. Although rare, 2 patients developed lymphoma during the study period. Although there is no causal relationship identified with the use of biologics, continuous monitoring of the long-term safety of these drugs in the paediatric cohort is recommended.